Published
2024-06-25
Issue
Section
Pharmacy Practice & Practice-Based Research
Categories
License
Copyright (c) 2024 Fawzy Elbarbry, Kate Farthing, Shannon Arguello
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright of content published in INNOVATIONS in pharmacy belongs to the author(s).
Diagnosis and Management of Daptomycin-Induced Acute Eosinophilic Pneumonia: A Case Report
Fawzy Elbarbry
Legacy Health
Kate Farthing
Legacy Health
Shannon Arguello
Legacy Health
DOI: https://doi.org/10.24926/iip.v15i2.6200
Keywords: Daptomycin, Acute Eosinophilic Pneumonia, Diagnosis, Management
Abstract
Daptomycin is a cyclic lipopeptide antibiotic that is indicated for the treatment of complicated skin infections and bacteremia caused by gram positive organisms. Acute eosinophilic pneumonia (AEP) is a rare, but serious adverse effect of daptomycin and caused by accumulation of eosinophils in the lung tissues, and can lead to respiratory failure. Early diagnosis and management of this condition is crucial to avoid severe complications, including death. Herein, we report a case of an elderly man who presented with signs and symptoms of AEP within two weeks of initiation of daptomycin for the treatment of MRSA bacteremia. The patient showed significant clinical improvement and decline in eosinophils upon discontinuation of daptomycin and starting a 5-day steroid course. Acute eosinophilic pneumonia should be kept in mind as a possible, although rare, adverse effect of daptomycin. Early recognition can be established through typical symptoms, eosinophilia, and chest X-ray showing pulmonary infiltrate. Rapid discontinuation of daptomycin with/without steroid therapy and supportive care usually results in significant clinical recover.
